Mikhail Blagosklonny: On A Mission To Defeat Cancer And Premature Aging

Mikhail Blagosklonny is an experienced educator and scientist. His area of specialization is cancer and aging. An oncology professor at New York’s Roswell Park Cancer Institute, he is known for his theory on TOR’s role in aging and cancer and the potential for treating it with rapamycin. Blagosklonny has published almost 300 articles in peer-reviewed publications and was editor-in-chief of Cell Cycle, Aging and Oncotarget, and Cancer Biology & Therapy’s associate editor. He’s on Cell Death & Differentiation’s editorial board.

A graduate of First Pavlov State Medical University of St. Petersburg, Blagosklonny has a PhD in Cardiology and Experimental Medicine and an M.D. in Internal Medicine. In 2002 he became a New York Medical College, Valhalla associate professor of medicine. He then became a senior scientist with Ordway Research Institute where he remained until 2009. Mikhail Blagosklonny was appointed a Roswell Park Cancer Institute professor of oncology. Part of what makes him such a good educator is his research and understanding of cancer, targeted cancer therapies to protect normal cells, anti-aging drugs and the mechanisms underlying aging.

Read more: Rejuvenating immunity: “anti-aging drug today” eight years later

His theories on the use of rapamycin to treat aging related issues have created growing interest in Mikhail Blagosklonny. His major point of emphasis is the role TOR plays in signaling what is going on in the body with aging and cancer in the body. He’s also a proponent of the use of the cancer drug rapamycin to treat ailments related to aging and improve and lengthen people’s lives. His work has helped to distinguish Blagosklonny as longevity research’s most passionate advocates for the use of rapamycin.

Cancer research is a core element of Blagosklonny’s mission. Mikhail Blagosklonny’s played a major role in some of the groundbreaking research being done in the field. He has helped many students, doctors and researchers to gain a greater understanding of cancer’s nature and has led to major advances in the diagnosis and treatment of the disease. His classes have provided students with a superior, comprehensive educational experience. Blagosklonny’s interests and research in molecular and cellular biology and their relationship to clinical investigations is legendary.

With the help of Mikhail Blagosklonny strategies like cellular senescence, cell cycle, signal transduction, and anticancer therapeutics which emphasize the creation of new anticancer treatments from the translation of basic science have grown in popularity. Blagosklonny has dedicated over 30 years of his life to the research and treatment of cancer and age related issues.

Find works by Mikhail Blagosklonny on PubPeer.com
Read more about Mikhail Blagosklonny on T and F Online

Seattle Genetics Hails As One Of The Top Therapeutic Companies In The Industry

Seeking Gal PHA recently reported in an online news article about the success of Seattle Genetics handing over their 10-Q financial records over to the SEC. This is a result of the Financial Awareness Conference that was recently held in New York City. Seattle Genetics aims to have the most transparent financial portfolio for their investors. NASDAQ has reported very good numbers for Seattle Genetics 2 quarters in a row. Clay Siegall, CEO of Seattle Genetics did a great job of providing the necessary documents for Executive Financial Officer, Peggy Pinkston to present to investors during the conference.

Clay Siegall did a great job of representing Seattle Genetics as a financially sound therapeutic company that is willing use scientific research in lymphoma studies to treat chronic pain. They’re proud to announce 5 upcoming clinical trials to continue their long history of helping the public remain healthy through profound medical technological advances. The primary goal is to advance the development of micro MRA based therapeutics which is still under extensive research. Seattle Genetics looks forward to working with the team to advance the healthcare needs of the people. Individuals suffering from chronic pain get the treatment that they deserve.

Seattle Genetics was confounded in 1998 and is currently under new leadership. They have create extensive therapies that address the medical needs of the people. You get specialized care from a list of services that will meet the demands of an aging community, the need for medical care, and people that have difficulty affording medical care. He has gotten a positive therapeutic response from the the community and continues to keep the interests of the people at the forefront. There is no other therapeutic provider that leads the industry in putting the needs of the patients first. You’ll get treatment that is designed to maximize your overall health. Siegall is a generous fundraiser that also believes in giving back to the community. He has helped disadvantaged youth all across the world and encourage other organizations to give back when they’re able to. Visit Seattle Genetics on more information to get healthy today.

Sources:

http://seekingalpha.com/article/3991804-seattle-genetics-sgen-clay-b-siegall-q2-2016-results-earnings-call-transcript

https://www.crunchbase.com/person/clay-b-siegall#/entity